DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Genital neoplasm, female — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGenital neoplasm, female maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for genital neoplasm, female is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopamine receptor D4 (DRD4) — DRD4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet aqddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5WIU · 1.962 Å · ligand Nemonapride (AQD). Experimental structure, not a prediction.
What the evidence adds up to
In a series of 151 patients with rhabdomyosarcoma of the female genital tract treated on Intergroup Rhabdomyosarcoma Study Group protocols I–IV, the overall five-year survival was 82%, rising to 87% for patients with locoregional tumours. Chemotherapy was primarily vincristine, actinomycin-D, and cyclophosphamide (VAC) based. Local therapy consisted of surgery alone in 42% of patients, surgery plus radiotherapy in 19%, biopsy plus radiotherapy in 12%, and biopsy without radiotherapy in 21%. The rate of hysterectomy fell from 48% in IRS-I/II to 22% in IRS-III/IV, while use of radiotherapy increased from 23% in IRS-II to 45% in IRS-IV, with continued excellent survival. For patients with localised embryonal or botryoid tumours, there were no significant differences in five-year survival among different tumour sites or across the four protocols. In patients with Group I–III tumours, 43% of deaths were from toxicity. When toxic deaths were censored, age 1–9 years at diagnosis, noninvasive tumours, and treatment on IRS-II or IRS-IV were associated with significantly better outcome. Patients aged 1–9 years had a five-year survival of 98%; those outside this age range benefited from intensified therapy used in IRS-III or IRS-IV, with five-year survival rising from 67% on IRS-I/II to 90% on IRS-III/IV.
Multiple primary cancer of the female genital system is rarely reported. Two cases are described: one patient had primary endometrial cancer and right ovarian cancer, the other had primary cervical cancer and left ovarian cancer. Both received radical surgical resection and recovered without obvious complications. The authors note that distinguishing multiple primary neoplasms from metastatic disease is important because overall survival and treatment differ considerably. A 1983 survey also describes multiple primary neoplasms of the female genital tract as a well-recognised but rare occurrence, and states that the pathogenesis of neoplastic processes affecting tissues of different embryological origin requires further research and evaluation.
A 1990 review of pathology of gynaecologic malignancies discusses newly described neoplasms, results of analyses of large case series, recent revisions in terminology, and the application of newer techniques such as flow cytometry. No specific drug treatments or survival data are reported in that review.
What remains missing is prospective data on how to reduce treatment-related deaths in rhabdomyosarcoma—43% of deaths in Group I–III tumours were from toxicity—and how to stratify patients who can safely omit radiotherapy or hysterectomy without compromising survival. For multiple primary neoplasms, no large series or controlled treatment comparisons exist; the evidence rests on case reports and pathological classification.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 2001 · 139 citations · open access
What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
AbstractBACKGROUND: Factors affecting outcome for rhabdomyosarcoma (RMS) of the female genital tract in patients treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols I-IV were evaluated to define optimal therapy. METHODS: Records of 151 patients with tumors of the female genital tract who were treated on IRSG protocols I-IV were reviewed for details regarding chemotherapy, surgery, radiotherapy (RT), and outcome. RESULTS: The overall 5-year survival was 82%, (87% for patients with locoregional tumors). Chemotherapy was primarily vincristine, actinomycin-D, and cyclophosphamide (VAC) based. Local therapy was surgery alone in 42% of patients, surgery plus RT in 19% of patients, biopsy plus RT in 12% of patients, and biopsy without RT in 21% of patients. The rate of hysterectomy decreased from 48% in IRS-I/II to 22% in IRS-III/IV with an increase in the use of RT from 23% in IRS-II to 45% in IRS-IV and continued excellent survival. Many patients with vaginal primary tumors received delayed RT or had it omitted on later studies with excellent outcome. For patients with localized embryonal/botryoid tumors, there were no significant differences in 5-year survival among patients with tumors at different sites or among patients treated on IRS-I-IV. In patients with Group I-III tumors, 43% of deaths were from toxicity. Analysis of prognostic factors, with toxic deaths censored, revealed that an age of 1-9 years at the time of diagnosis, noninvasive tumors, and the use of IRS-II or IRS-IV treatments were associated significantly with better outcome. Patients ages 1-9 years fared best (5-year survival of 98%) and patients outside of this age range especially benefited from the intensified therapy used in IRS-III or IRS-IV (5-year survival of 67% on the IRS-I/II vs. 90% in IRS-III/IV). CONCLUSIONS: Localized female genital RMS usually is curable with combination chemotherapy, a conservative surgical approach, and the use of RT for selected patients.
Multiple primary cancer in the female genital system
AbstractRATIONALE: Multiple primary cancer (MPC) refers to tumors that occur in one or multiple organs within the same patient at the same time or at different periods. MPC often occurs in the head and neck, but is rarely reported in the female genital system. PATIENT CONCERNS: In the present study, we report 2 rare cases that presented with tangible lower abdominal tumors. DIAGNOSES: Laboratory tests, pelvic ultrasound (US), computed tomography (CT), and fast histopathological examinations during surgery indicated a diagnosis of MPC. INTERVENTIONS: The 2 patients all received radical resections of multiple tumors. OUTCOMES: Postsurgical histopathological and immunohistochemical examinations further confirmed primary endometrial cancer and right ovarian cancer in Case 1, and primary cervical cancer and left ovarian cancer of Case 2. The 2 patients all recovered well without obvious complications. LESSONS: Our study demonstrated that female genital MPC should be noted for patients with multiple genital tumors. In addition, accurately diagnosis and radical surgical treatment should be well performed.
Seminars in Surgical Oncology · 1990 · 2 citations
Pathology of gynecologic malignancies
AbstractThis review encompasses advances in the pathology of female genital tract tumors that have been deemed to have clinical significance. A number of newly described neoplasms are discussed as are the results of analyses of large series of cases of previously described tumors. Recent revision in terminology and the application of newer techniques for evaluating neoplasms, such as flow cytometry, are also briefly reviewed.
Conical slotted screens for centrifugal grates (a survey)
AbstractMultiple primary neoplasms of female genital tract is a well-recognized yet rare occurrence. Although the presented case is probably an incidental event, the pathogenesis of the neoplastic process affecting the tissues with different embryological origin needs further research and evaluation. It is important to distinguish multiple primary neoplasms from metastatic disease because of the fact that overall survival as well as treatment would vary considerably.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
